Company Performance Metrics
Volker Schellenberger: Co-Founder, President, and CTOPast Role: Genencor International, Head of Protein Engineering
Walter H. Moos: Board MemberPast Role: SRI International, President, SRI Biosciences; Vice President, SRI International
Amunix is a biopharmaceutical company intended to discover, design, and develop novel biologics, protein, and peptide therapeutics. The company is focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers. By delivering breakthrough therapies that can safely harness the
immune system, it aims to conquer cancer and save lives. Its pipeline products are based on its proprietary XTEN half-life extension, XDC drug-conjugate delivery, and ProTIA pro-drug, bispecific T cell engager platform and have ongoing collaborations with biopharma corporations harnessing these delivery technologies over a wide range of therapeutic areas, delivering improved pharmaceutical technologies.
Amunix was founded in 2006 and is headquartered in Mountain View, California.
